

Open Peer Review on Qeios

Autologous Anti-CD19 Chimeric Antigen Receptor T-cells SJCAR19

National Cancer Institute

Source

National Cancer Institute. <u>Autologous Anti-CD19 Chimeric Antigen Receptor T-cells</u>
<u>SICAR19</u>. NCI Thesaurus. Code C142887.

A proprietary preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19 and containing, as of yet undisclosed, costimulatory signaling domains, with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-CD19 CAR T-cells SJCAR19 target and bind to CD19-expressing tumor cells, thereby inducing selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.

Qeios ID: K7XGYO · https://doi.org/10.32388/K7XGYO